No consistency in endophthalmitis prophylaxis

Article

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Patel Gordon-Bennett of the department of ophthalmology at Hinchingbrooke Hospital, Cambridgeshire, UK and colleagues conducted a telephone interview survey with 800 staff from ophthalmic training units across the UK between October and November 2005.

The team found that 99.4% of surgeons (n=795) used a preoperative preparation of povidone-iodine on the skin; 69.8% (n=558) instilled povidone-iodine into the conjunctival sac; and 5.9% (n=47) administered antibiotic eyedrops. During surgery, 17.8% (n=142) administered intracameral antibiotics: 66.4% (n=531) administered subconjunctival cefuroxime, 6.0% (n=48) administered routine gentamycin and 4.9% (n=39) administered alternative subconjunctival antibiotics; 16.8% (n=134) administered topical drops as a single dose. Combination steroid/neomycin drops were used by 64.4% of surgeons (n=515) postoperatively; 26.6% (n=213) administered separate drops.

The study revealed wide variation in the preventative measures employed by surgeons. The most frequently deployed methods of endophthalmitis prophylaxis are administrations of subconjunctival and intracameral cefuroxime.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.